EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSBTAG00000020667
Gene Symbol: KCNQ3
3 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSBTAG00000007791
Gene Symbol: KCNQ5
3 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSBTAG00000011757
Gene Symbol: PSEN1
17 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSBTAG00000013197
Gene Symbol: PSEN2
14 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSBTAG00000018593
Gene Symbol: PSENEN
14 Enzyme and pathways 5 Cross references
197 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme

Ensembl ID : ENSBTAG00000001041
Gene Symbol: LOC100138645
3 Enzyme and pathways 4 Cross references
321 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSBTAG00000024648
Gene Symbol: PGR
16 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSBTAG00000006703
Gene Symbol: PTGDR
8 Enzyme and pathways 5 Cross references
120 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSBTAG00000039652
Gene Symbol: PTGDR2
8 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Prostaglandin E Receptor 1

Ensembl ID : ENSBTAG00000017041
Gene Symbol: PTGER1
8 Enzyme and pathways 5 Cross references
248 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSBTAG00000002163
Gene Symbol: PTGER2
8 Enzyme and pathways 5 Cross references
254 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSBTAG00000019230
Gene Symbol: PTGER3
8 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).